Anthony R. Prosser, Ph.D., is a Registered Patent Agent with Knowles Intellectual Property Strategies (KIPS) in Atlanta, Georgia, and is also currently a law student at Georgia State University.  Tony focuses on complex organic chemistry patent matters including drafting and prosecuting U.S. and international patent applications directed to new chemical compounds and synthetic methodology, due diligence, freedom to operate analysis, and patentability investigations.  Tony’s technical areas of expertise include organic synthesis, process chemistry, medicinal chemistry, nucleoside chemistry and drug discovery and development.

​

Prior to joining the firm, Tony received his Ph.D. in Organic Chemistry from Emory University under Dr. Dennis S. Liotta, the Samuel Candler Dobbs Professor of Chemistry and an internationally acknowledged leader in academic drug discovery.  At Emory, Tony was awarded a Woodruff Fellowship as well as a NSF Graduate Fellowship.  Tony’s graduate work focused on the development of a series of molecules that inhibit CXCR4, CCR5, and HIV Reverse Transcriptase simultaneously.  The series is currently being pursued as a single agent for the therapeutic treatment of HIV. Tony identified a new synthetic route to produce a known pharmaceutical intermediate in two steps that at the time required a six-step synthesis that produced less than a 10% yield.  Tony’s novel synthetic path not only reduced the number of synthetic steps to two, it increased the yield by an order of magnitude. During his doctoral work, Tony made over 100 HIV entry inhibitors for structure activity analysis. Emory University filed a patent application on his graduate work to cover the synthesis and use of his new HIV agents. Tony’s doctoral research was featured in Chemical and Engineering News, Science Daily, A&U Magazine, and was awarded first place in the campus wide Emory University 3-Minute Thesis Competition.

​

Tony also had an impressive path through undergraduate studies at the University of Kansas. He had already taken nine AP courses (receiving a perfect “5” in each) and several community college courses, which allowed him to begin his study of chemistry at KU in 2008 with over 50 hours of college credit. Tony began his first year of college as a second semester sophomore. The University of Kansas awarded him a full scholarship package that covered all costs, including living expenses, and included the top academic and leadership awards available. His academic rigor continued at KU where he began synthetic work his first semester, taught several sections of General Chemistry Lab (a role more typically filled by Graduate Teaching Assistants), and helped found the PLUS Chemistry Program.  During his three-year undergraduate study, Tony received over a dozen academic awards/honors, including the University’s Goldwater Nomination, the Darlington Research Award, and the American Institute of Chemists Fellow Award for Excellence in Chemistry. Tony’s undergraduate research focused on new donor-acceptor cyclopropanes for use as synthetic tools in the production of more complex natural or medicinal products. He received a B. S. in Chemistry in 2011 with honors and was one of twelve featured graduates.

​

Selected Publications include:

​

• One-Pot Transformation of Esters to Analytically Pure Ketones: Methodology and Application in Process Development. Anthony R. Prosser, and Dennis C. Liotta; 56, 3005-3007 Tetrahedron Letters 2

• Discovery of Novel N-Aryl Piperazine CXCR4 Antagonists. Zhao, H.; Anthony R. Prosser; Liotta, D. C.; Wilson, L. J.; 25, 4950-4955 Med. Chem. Lett. 2015.

• Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase. Cox, B. D.; Anthony R. Prosser; Sun, Y.; Li, Z.; Lee, S.; Huang, M. B.; et al.; 6, 753-757 ACS Medicinal Chemistry Letters

• NMDA Receptor Modulators: An Updated Patent Review (2013-2014). Katie L. Strong, Yao Jing, Anthony R Prosser, Stephen F. Traynelis, and Dennis C. Liotta; 24, 1349-1366 Expert Opinion on Therapeutic Patents

• Anti-HIV Small Molecule Binding in the Peptide Sub-Pocket of the CXCR4:CVX15 Crystal Structure. Bryan D. Cox, Anthony R. Prosser, Brooke M. Katzman, Ana A. Alcaraz, et al.; 15(11) 1614-1620 BioChem. 2014.

• Formal Substitution of Bromocyclopropanes with Nitrogen Nucleophiles. Joseph E. Banning, Jacob Getillon, Pavel G. Ryabchuk, Anthony R. Prosser, et al.; 78(15) 7601-7616 Org. Chem. 2013.

• Discovery of Tetrahydroisoquinoline-Based CXCR4 Antagonist. Valarie M. Trauax, Huanyu Zhao, Brooke M. Katzman, Anthony R. Prosser, et al.; 4(11) 1025-1030 ACS Med. Chem. Lett.

• Diastereoselective Control in Formal Nucleophilic Substitution of Bromocyclopropanes with Oxygen and Sulfur-Based Nucleophiles. Joseph E. Banning, Anthony R. Prosser, Bassam K. Alnasleh, et al.; 76(10), 3968-3986, Org. Chem. 2011.

• Formal Nucleophilic Substitution of Bromocyclopropanes with Amides en route to Conformationally Constrained b-Amino Acid Derivatives. Anthony R. Prosser, Joseph E. Banning, Marina Rubina, Michael Rubin; 12(18), 3968-3971, Lett. 2010.

• Thermodynamic Control of Diastereoselectivity in the Formal Nucleophilic Substitution of Bromocyclopropanes. Joseph E. Banning, Anthony R. Prosser, Michael Rubin; 12(7), 1488-1491, Lett. 2010.

​

​